Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.56 |
| ▸ | CA2 | P00918 | 11/20 | 0.56 |
| ▸ | CA9 | Q16790 | 9/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 4/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19734 | 0.97 | — | — | |
| Phosphine SCHEMBL27878832 | 0.95 | CA1 (0.56) | CA1CA2CA9CA12CA7 | |
| SCHEMBL17456625 | 0.95 | CA1 (0.56) | CA1CA2CA9CA12CA7 | |
| Hydrochloric Acid SCHEMBL27206830 | 0.95 | CA1 (0.56) | CA1CA2CA9CA12CA7 | |
| Ammonia Solution, Strong SCHEMBL635964 | 0.95 | CA1 (0.56) | CA1CA2CA9CA12CA7 | |
| SCHEMBL27918238 | 0.95 | CA1 (0.56) | CA1CA2CA9CA12CA7 | |
| Ethane SCHEMBL28406834 | 0.95 | CA1 (0.56) | CA1CA2CA9CA12CA7 | |
| SCHEMBL17456495 | 0.95 | CA1 (0.56) | CA1CA2CA9CA12CA7 | |
| Phosphine SCHEMBL3823811 | 0.95 | CA1 (0.56) | CA1CA2CA9CA12CA7 | |
| SCHEMBL27424529 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633609-A1 | LIPID NANOPARTICLES LYOPHILIZATION METHODS AND COMPOSITIONS | Global Life Sciences Solutions Canada ULC (CA) | 2025-10-22 | — | — | EP | claimed |
| EP-4512475-A2 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | Gilead Sciences, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| EP-3651734-B1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES INC (US) | 2024-11-13 | — | — | EP | claimed |
| WO-2024126423-A1 | LIPID NANOPARTICLES LYOPHILIZATION METHODS AND COMPOSITIONS | Precision NanoSystems ULC (CA) | 2024-06-20 | — | — | WO | claimed |
| US-20240148700-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATION | ALDEYRA THERAPEUTICS, INC. | 2024-05-09 | — | — | US | claimed |
| US-11975017-B2 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | claimed |
| CN-117982682-A | Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections | 吉利德科学公司 | 2024-05-07 | — | — | CN | claimed |
| US-20240091251-A1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-03-21 | — | — | US | claimed |
| CN-111093627-B | Compositions comprising an RNA polymerase inhibitor and a cyclodextrin for treating viral infections | 吉利德科学公司 | 2024-03-08 | — | — | CN | claimed |
| US-20240024341-A1 | INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | claimed |
| EP-1819350-A2 | PHARMACEUTICAL FORMULATIONS CYTIDINE ANALOGS AND DERIVATIVES | SuperGen, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| EP-1819227-A1 | PHARMACEUTICAL FORMULATION OF DECITABINE | SuperGen, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006071491-A1 | PHARMACEUTICAL FORMULATION OF DECITABINE | SUPERGEN, INC. (US) | 2006-07-06 | — | — | WO | claimed |
| US-20060128653-A1 | Pharmaceutical formulation of decitabine | SUPERGEN, INC. | 2006-06-15 | — | — | US | claimed |
| WO-2006063111-A2 | PHARMACEUTICAL FORMULATIONS CYTIDINE ANALOGS AND DERIVATIVES | SUPERGEN, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-20060128654-A1 | Pharmaceutical formulation of cytidine analogs and derivatives | SUPERGEN, INC. | 2006-06-15 | — | — | US | claimed |
| US-20040053888-A1 | Cyclodextrin-containing pharmaceutical preparation | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-03-18 | — | — | US | claimed |
| EP-1348432-A1 | CYCLODEXTRIN-CONTAINING PHARMACEUTICAL PREPARATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-10-01 | — | — | EP | claimed |
| US-6596706-B1 | For the treatment of circulatory diseases cerebral diseases | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | claimed |
| EP-1029872-A1 | PIPERAZINE-CYCLODEXTRIN COMPLEXES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091251-A1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | CTDSP1, RNGTT, POLRMT | CA1 3296/4885CA2 2028/4885CA9 2168/4885 |
| US-20240148700-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATION | PDE6C, PDE6H, PDE6D | CA1 4805/4885CA2 2516/4885CA9 2739/4885 |
| US-11975017-B2 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | CTDSP1, RNGTT, POLRMT | CA1 3296/4885CA2 2028/4885CA9 2168/4885 |
| US-20240024341-A1 | INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | SLC29A1, SLC28A1, RNMT | CA1 835/4885CA2 428/4885CA9 493/4885 |
| US-20040053888-A1 | Cyclodextrin-containing pharmaceutical preparation | SLCO2B1, RPS27L, SEC23IP | CA1 4010/4885CA2 3158/4885CA9 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.